Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) strive to create alternatives to injectable drugs.
製造業-半導體公司如羅氏控股(OTC:RHHBY),禮來(NYSE:LLY),諾和諾德(NYSE:NVO)和輝瑞(NYSE:PFE)正競相開發口服減肥藥物,力圖爲注射藥物打造替代品。
While these pills offer a promising solution in the fight against obesity, experts caution that they may not wholly replace injectable options.
雖然這些藥丸在對抗肥胖症方面提供了一種有希望的解決方案,但專家們警告稱,它們可能無法完全取代注射選項。
Clinical trial data indicate that oral medications could match injectable drugs' effectiveness and side effects. However, to mitigate side effects, they may require more frequent dosing or produce slightly less weight loss.
臨床試驗數據表明,口服藥物可能與注射藥物的功效和副作用相匹配。然而,爲了減輕副作用,它們可能需要更頻繁的服藥或產生稍微較少的減重效果。
Related: Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications.
相關:因追逐奧澤匹克和澤博聯合減肥而無關鍵GLP-1藥物的糖尿病患者。
Forbes report noted that oral medications offer significant advantages over injectables, such as reduced manufacturing costs and eliminating the need for refrigeration.
福布斯的一份報告指出,與注射藥物相比,口服藥物具有顯著的優勢,例如降低製造成本和消除冷藏需求。
Sun Kim, an endocrinologist at Stanford, pointed out that while some patients are comfortable with injector pens, others find injections daunting and would benefit from oral alternatives. However, the journey from development to market for these pills could take several years.
斯坦福大學的內分泌學家Sun Kim指出,雖然一些患者對注射筆感到舒適,但其他人發現注射令人畏懼,會從口服藥物中獲益。但是,這些藥丸從開發到上市可能需要幾年時間。
Novo Nordisk is leading the charge with Rybelsus, the only authorized oral GLP-1 drug. However, the Danish company faces production challenges and has delayed seeking regulatory approval for Rybelsus as a weight loss drug.
諾和諾德以其唯一的授權口服GLP-1藥物Rybelsus領先於其他藥企。然而,這家丹麥公司面臨生產挑戰,並已推遲尋求Rybelsus作爲減肥藥物的監管批准。
Meanwhile, Eli Lilly and Pfizer are developing promising daily pills, orforglipron and danuglipron, and Roche is reporting encouraging results from early-stage trials of its candidates.
同時,禮來和輝瑞正在開發有前途的每日用藥,即orforglipron和danuglipron,而羅氏則報告了其候選藥物早期試驗的令人鼓舞的結果。
Environmental concerns also contribute to the shift toward oral medications. Injectable therapies like GLP-1 agonists generate significant medical waste, with each dose often requiring a separate pen.
環保問題也對轉向口服藥物做出了貢獻。GLP-1激動劑等注射治療方法產生了大量醫療廢物,每劑藥物通常需要一支注射筆。
GLP-1 agonists, such as Ozempic, Wegovy, Mounjaro, and Zepbound, have gained popularity for their effectiveness in weight loss by mimicking a hormone that regulates blood sugar and appetite. Progress is being made despite the challenge of formulating oral versions of peptide-based drugs.
GLP-1激動劑如奧澤匹克(Ozempic),Wegovy,Mounjaro和Zepbound,因其模擬調節血糖和食慾的激素而在減肥方面變得越來越受歡迎。儘管在制定基於肽的藥物的口服版本方面存在挑戰,但已在取得進展。
Daniel Drucker, an endocrinologist at the University of Toronto, noted that while protein therapeutics like insulin are predominantly injectable, effective oral formulations are possible, as Novo's Rybelsus demonstrated.
多倫多大學的內分泌學家Daniel Drucker指出,儘管蛋白質治療如胰島素主要是注射劑形式,但有效的口服制劑是可能的,正如諾和諾德的Rybelsus所證明的那樣。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明:本內容部分使用人工智能工具生成,並經Benzinga編輯審核發佈。
- Obesity-Drugs Focused Stocks Tumble On Wednesday – What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
- 肥胖藥物專注的股票週三下跌,Eli Lilly、Novo Nordisk、Viking Therapeutics、Structure Therapeutics發生了什麼?
Photo via Shutterstock
圖片來自shutterstock。